Desvenlafaxine: a new antidepressant or just another one?

Bibliography

• Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105
   PubMed Web of Science ®Google Scholar
• Kessler RC, Merikangas KR, Wang PS. Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century. Annu Rev Clin Psychol 2007;3:137-58
   PubMed Web of Science ®Google Scholar
• Kessler RC, Merikangas KR, Wang PS. The prevalence and correlates of workplace depression in the national comorbidity survey replication. J Occup Environ Med 2008;50:381-90
   PubMed Web of Science ®Google Scholar
• Keitner GI, Solomon DA, Ryan CE. STAR*D: have we learned the right lessons? Am J Psychiatry 2008;165:133; author reply 133-4
   PubMed Web of Science ®Google Scholar
• Warden D, Rush AJ, Trivedi MH, et al. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep 2007;9:449-59
   PubMedGoogle Scholar
• Dmochowski RR, Staskin DR. Advances in drug delivery: improved bioavailability and drug effect. Curr Urol Rep 2002;3:439-44
   PubMedGoogle Scholar
• Keith S. Advances in psychotropic formulations. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:996-1008
   PubMed Web of Science ®Google Scholar
• Norman TR, Olver JS. New formulations of existing antidepressants: advantages in the management of depression. CNS Drugs 2004;18:505-20
   PubMed Web of Science ®Google Scholar
• DeMartinis NA, Yeung PP, Entsuah R, Manley AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2007;68:677-88
   PubMed Web of Science ®Google Scholar
• Septien-Velez L, Pitrosky B, Padmanabhan SK, et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 2007;22:338-47
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry 2007;68:1663-72
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Manley AL, Padmanabhan SK. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 2008;24(7):1877-90
   PubMed Web of Science ®Google Scholar
• Lieberman DZ, Montgomery SA, Tourian KA, et al. A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol 2008;23:188-97
   PubMed Web of Science ®Google Scholar
• Speroff L, Gass M, Constantine G, Olivier S. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111:77-87
   PubMed Web of Science ®Google Scholar
• Patroneva A. The effects desvenlafaxine succinate and paroxetine on the pharmacokinetics of desipramine on healthy adults. wyeth, NCDEU
   Google Scholar
• Deecher DC. Physiology of thermoregulatory dysfunction and current approaches to the treatment of vasomotor symptoms. Expert Opin Investig Drugs 2005;14:435-48
   PubMed Web of Science ®Google Scholar
• Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006;318:657-65
   PubMed Web of Science ®Google Scholar
• Wyeth. Highlights of prescribing information
   Google Scholar
• Preskorn S. Comparing the pharmacokinetics of venlafaxine extended release and desvenlafaxine succinate in healthy subjects who are extensive and poor metabolizers via cytochrome P450 (CYP) 2D6. Wyeth, NCDEU
   Google Scholar
• Parks VPA, Behrle J. Safety, pharmacokinetics and pharmacodynamics of ascending single oral doses of sustained-release desvenalafaxine succinate in healthy subjects [poster]. Presented at the meeting of the American society for clinical pharmacology and therapeutics, 2–5 March 2005, Orlando, Florida, USA
   Google Scholar
• Shilling A, Young-Sciame R, Leung L. Comparison of inhibitory effects of desvenlafaxine succinate, venlafaxine, SS duloxetine, paroxetine, sertraline and bupropion on human cytochrome P450 activities. Poster presented at International Society for the Study of Xenobiotics, 25–27 October 2005, Maui, Hawaii, USA
   Google Scholar
• Alfinito PD, Huselton C, Chen X, Deecher DC. Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats. Brain Res 2006;1098:71-8
   PubMed Web of Science ®Google Scholar
• Mason JN, Deecher DC, Richmond RL, et al. Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther 2007;323:720-9
   PubMedGoogle Scholar
• Feiger AD, Tourian KA, Rosas GR, Padmanabhan SK. A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder. CNS Spectr 2009;14:41-50
   PubMed Web of Science ®Google Scholar
• Thase ME, Kornstein SG, Tummala R, et al. An integrate d analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depresive disorder [abstract NR5-125]. Presented at the 161st annual meeting of the American Psychiatric Association, 3–8 May 2008, Washington, DC, USA
   Google Scholar
• Patroneva A, Kornstein SG, Fava M, et al. Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine succinate or placebo [abstract NR5-082]. Program and abstracts of the American Psychiatric Association 161st Annual Meeting, 3–8 May 2008, Washington, DC
   Google Scholar
• Soares CN, Thase ME, Kornstein SG, et al. Assessing the efficacy of desvenlafaxine for improving functioning and quality of life measures in patients with major depressive disorder [abstract NR5-089]. Program and abstracts of the American Psychiatric Association 161st Annual Meeting, 3–8 May 2008, Washington, DC, USA
   Google Scholar
• Rickels K, Montgomery SA, Tourian KA, et al. A multi-center, randomized, double-blind, placebo-controlled, parallel-group study of desvenlafaxine succinate for prevention of depressive relapse in adult outpatients with major depressive disorder [poster presentation]. Presented at the 160th Annual Meeting of the American Psychiatric Association, 19–24 May 2007, San Diego, California, USA
   Google Scholar
• Ferguson J, Tourian KA, Rosas GR, et al. A 12-month open-label evaluation of long-term safety and efficacy of desvenlafaxine succinate in outpatients with major depressive disorder [poster presentation]. Presented at the 160th Annual Meeting of the American Psychiatric Association, 19–24 May 2007, San Diego, California, USA
   Google Scholar
• Deecher DC, Alfinito PD, Leventhal L, et al. Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized rodent models. Endocrinology 2007;148:1376-83
   PubMed Web of Science ®Google Scholar
• Cheema D, Coomarasamy A, El-Toukhy T. Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidence-based review. Arch Gynecol Obstet 2007;276:463-9
   PubMedGoogle Scholar
• Steiner MK, Yu L, Bobula H, Oliver J. Desvenlafaxine improves mood in women treated for vasomotor symptoms: effect of baseline mood states [poster presentation]. Presented at the 160th Annual Meeting of the American Psychiatric Association, 19–24 May 2007, San Diego, California, USA
   Google Scholar
• Steiner MS, Kirby CN, Yu L, et al. Symptom reduction in women treated with desvenlafaxine for menopausal hot flushes: impact of bothersomeness [poster presentation]. Presented at the 160th Annual Meeting of the American Psychiatric Association, 19–24 May 2007, San Diego, California, USA
   Google Scholar
• Brisard CN, Germain PT, Ahmed JM, et al. Treating the painful physical symptoms of depression with desvenlafaxine succinate versus placebo in depressed outpatients. [poster presentation]. Presented at the 160th Annual Meeting of the American Psychiatric Association, 19–24 May 2007, San Diego, California, USA
   Google Scholar
• Kroenke K, Messina N 3rd, Benattia I, et al. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder. J Clin Psychiatry 2006;67:72-80
   PubMedGoogle Scholar
• Han C, Pae CU, Lee BH, et al. Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder: a 12-week prospective, open-label, randomized, parallel-group trial. Clin Drug Investig 2008;28:251-61
   PubMedGoogle Scholar
• Thomson. Annual report 2006 ‘Leading the way to a healthier world’. 2007
   Google Scholar
• Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974-84
   PubMed Web of Science ®Google Scholar
• Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5-15
   PubMed Web of Science ®Google Scholar
• Vitton O, Gendreau M, Gendreau J, et al. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004;19(Suppl 1):27-35
   PubMed Web of Science ®Google Scholar
• Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005;32:1975-85
   PubMed Web of Science ®Google Scholar
• Ahmed SP, Graepel A, Pitrosky J. Improvement of anxiety symptoms in patients with major depresive disorder treated with desvenlafaxine: a pooled analysis [abstract NR3-145]. Program and abstracts of the American Psychiatric Association 161st Annual Meeting, 3-8 May 2008, Washington, DC, USA
   Google Scholar
• Tourian KA, Patroneva A, Zitek A, et al. Improvement of anxiety symptoms in patients with major depressive disorder treated with desvenlafaxine succinate: a pooled analysis. Presented at the 160th Annual Meeting of the American Psychiatric Association, 19-24 May 2007, San Diego, California, USA
   Google Scholar
• Lohoff FW, Rickels K. Desvenlafaxine succinate for the treatment of major depressive disorder. Expert Opin Pharmacother 2008;9:2129-36
   PubMed Web of Science ®Google Scholar
• Guico-Pabia CA, Jiang S, Patroneva Q, et al. Efficacy folowing switch from venlafaxine to desvenlafaxine in responders versus nonresponders [abstract NR5-088]. Program and abstracts of the American Psychiatric Association 161st Annual Meeting, 3–8 May 2008, Washington, DC, USA
   Google Scholar
• Ahmed SZ, Ninan PT, Pitrosky B, et al. Switch from venlafaxine to desvenlafaxine succinate is well tolerated in patients with major depressive disorder [poster presentation]. Presented at the 160th Annual Meeting of the American Psychiatric Association, 19–24 May 2007, San Diego, California, USA
   Google Scholar
• Montgomery SF, Tourian KA, Padmanabhan SK, Guico-pabia C. Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depresive disorder [abstract NR5-038]. Program and abstracts of the American Psychiatric Association 161st Annual Meeting, 3-8 May 2008, Washington, DC, USA
   Google Scholar
• Nelson JC, Lu Pritchett Y, Martynov O, et al. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. Prim Care Companion J Clin Psychiatry 2006;8:212-19
   PubMedGoogle Scholar
• Clayton AH, Kornstein SG, Rosas G, et al. Pooled Analysis of the safety and tolerability of desvenlafaxine compare d with placebo in the treatment of major depresive disorder [abstract NR5-083]. Program and abstracts of the American Psychiatric Association 161st Annual Meeting, 3-8 May 2008, Washington, DC, USA
   Google Scholar
• Thase ME, Tourian KA. Blood presure changes with fixed-dose desvenlafaxine sucinate : pooled results from five placebo-controled, studies in depresed outpatients [abstract NR5-036]. Program and abstracts of the American Psychiatric Association 161st Annual Meeting, 3-8 May 2008; Washington, DC, USA
   Google Scholar
• Patroneva A, Ninan P, Tourian K, et al. Analysis of weight change with short- and longer-term treatment with desvenlafaxine succinate for major depressive disorder [abstract NR364]. Program and abstracts of the American Psychiatric Association 161st Annual Meeting, 3-8 May 2008, Washington, DC, USA
   Google Scholar
• Thase ME, Pritchett YL, Ossanna MJ, et al. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 2007;27:672-6
   PubMed Web of Science ®Google Scholar
• Pae CU, Masand P. Duloxetine: a new psychopharmacologic treatment option for fibromyalgia? Curr Psychiatry Rep 2008;10:237-9
   PubMedGoogle Scholar
• Briley M. New hope in the treatment of painful symptoms in depression. Curr Opin Investig Drugs 2003;4:42-5
   PubMedGoogle Scholar
• Briley M. Clinical experience with dual action antidepressants in different chronic pain syndromes. Hum Psychopharmacol 2004;19(Suppl 1):21-5
   PubMed Web of Science ®Google Scholar
• Perahia DG, Pritchett YL, Kajdasz DK, et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res 2008;42:22-34
   PubMed Web of Science ®Google Scholar
• Lenox-Smith AJ, Jiang Q. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Int Clin Psychopharmacol 2008;23:113-19
   PubMed Web of Science ®Google Scholar